Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6856861 | 0.85 | THRB (0.51) | PPARAKEAP1NFE2L2PPARGFFAR4 | |
| SCHEMBL6849586 | 0.84 | OPRK1 (0.42) | PPARAKEAP1NFE2L2MRGPRX4FFAR4 | |
| SCHEMBL6855496 | 0.83 | CTRC (0.43) | PPARAKEAP1NFE2L2PPARGMRGPRX4 | |
| SCHEMBL6936062 | 0.82 | KEAP1 (0.40) | PPARAKEAP1NFE2L2MRGPRX4FFAR4 | |
| SCHEMBL28786148 | 0.80 | THRB (0.46) | PPARAPPARGFFAR4OPRK1 | |
| SCHEMBL6852831 | 0.80 | KEAP1 (0.36) | PPARAKEAP1NFE2L2MRGPRX4AR | |
| SCHEMBL6854271 | 0.76 | PPARA (0.40) | PPARAPPARG | |
| SCHEMBL6852995 | 0.74 | KEAP1 (0.47) | KEAP1NFE2L2KMT2ABCL2L1MCL1 | |
| SCHEMBL7089153 | 0.73 | KEAP1 (0.46) | KEAP1NFE2L2KMT2ABCL2L1MCL1 | |
| SCHEMBL28786138 | 0.71 | THRB (0.49) | PPARAPPARGFFAR4OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777442-B2 | Diphenyl derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-17 | — | — | US | disclosed |
| EP-1370523-A1 | DIPHENYL DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030105078-A1 | Diphenyl derivatives | BAYER AKTIENGESSELLSCHAFT (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002072539-A1 | DIPHENYL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105078-A1 | Diphenyl derivatives | DPP4, DPP3, DPM1 | PPARA 52/4885FBP1 1925/4885KEAP1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.